Atrogi doses first patient in diabetes study
The Swedish pharmaceutical firm is initiating a phase I study of a molecule for the treatment of type 2 diabetes.
by christian bundgaard, translated by daniel pedersen
Swedish pharmaceutical firm Atrogi has started a phase I trial of a first-in-class drug candidate for type 2 diabetes treatment, a press release from the privately owned company announces.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
